5:49 PM
 | 
Jan 31, 2013
 |  BC Extra  |  Company News

NICE rebuffs Avastin for ovarian cancer

The U.K.'s NICE issued draft guidance recommending against the use of Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat recurrent advanced ovarian cancer in combination with gemcitabine and carboplatin. The committee said there was "insufficient evidence" of Avastin's effect on overall survival (OS) in...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >